Tyrogenex is a biopharmaceutical company specializing in developing dual vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) inhibitors for wet age-related macular degeneration (wet AMD) and solid tumors.
Tyrogenex’s lead compound is called X-82. X-82 inhibits both VEGFR and PDGFR. Tyrogenex believes X-82 targets the basic mechanisms of neovascular eye diseases, including angiogenesis, fibrosis and inflammation. X-82 is currently in Phase 2 human clinical trials for, Wet AMD, Renal Cell Carcinoma, Pancreatic Neuroendocrine Tumors and Advanced Solid Tumors.